Program
Esomeprazole
Also written as “esomeprazole”, “PN400” and “Esomeprazole (Nexium)”.
Its studies are mostly in Gastroesophageal Reflux · Stomach Ulcer · Heartburn · Esophagitis, Peptic · Gastrointestinal Diseases, led by 15 companies.
Drug pageEsomeprazole: every studyMany companies study it; this page follows only the 122 they lead. All 244 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 920 open or running | phase 4since Sep 12, 2005 | Mar 16, 2004 | none ahead |
| Hanmi Pharmaceuticalits history only | 50 open or running | phase 3since Sep 4, 2019 | Dec 8, 2017 | none ahead |
| Aralez Pharmaceuticalsits history only | 40 open or running | phase 1since Jan 11, 2008 | Jan 11, 2008 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 30 open or running | phase 1since Feb 6, 2018 | Feb 6, 2018 | none ahead |
| Pfizerits history only | 30 open or running | phase 4since Jan 21, 2016 | Feb 25, 2012 | none ahead |
| Takedaits history only | 30 open or running | phase 2since Apr 14, 2016 | Jul 16, 2009 | none ahead |
| Torrent Pharmaceuticalsits history only | 30 open or running | phase 1since Nov 9, 2015 | Nov 9, 2015 | none ahead |
| EMSits history only | 20 open or running | phase 4since Sep 2, 2015 | Sep 2, 2015 | none ahead |
| Elpen Pharmaceuticalits history only | 10 open or running | phase 4since Nov 7, 2016 | Nov 7, 2016 | none ahead |
| Eurofarma Laboratoriosits history only | 10 open or running | phase 3since Oct 31, 2011 | Oct 31, 2011 | none ahead |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Sep 6, 2021 | Sep 6, 2021 | none ahead |
| HALEONits history only | 10 open or running | phase 1since Feb 22, 2022 | Feb 22, 2022 | none ahead |
| Johnson & Johnsonits history only | 10 open or running | phase 4since Apr 20, 2007 | Apr 20, 2007 | none ahead |
| Joincare Pharmaceutical Group Industryits history only | 11 open or running | phase 3since Feb 7, 2025 | Feb 7, 2025 | none ahead |
| SD Biosensorits history only | 10 open or running | phase 4since Jan 19, 2009 | Jan 19, 2009 | none ahead |
Also a collaborator on its studies: IQVIA RDS, Laboratory Corporation of America, Medidata Solutions, Thermo Fisher Scientific, CISCRP, Arvinas Estrogen Receptor, Parexel and Quintiles.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since May 8, 2008.
- Dec 8, 2017Hanmi Pharmaceutical’s first study: phase 1 study in HealthyNew to Hanmi PharmaceuticalHanmi Pharmaceutical · NCT03372850 · 96 enrolled · Korea, Republic of
- Feb 6, 2018Chong Kun Dang Pharmaceutical’s first study: phase 1 study in Gastroesophageal RefluxNew to Chong Kun Dang PharmaceuticalChong Kun Dang Pharmaceutical · NCT03444402 · 18 enrolled · Korea, Republic of
- Apr 5, 2018Phase 3 study in Esophagitis, PepticAstraZeneca · NCT03553563 · 50 enrolled · Japan
- Jun 1, 2018Phase 1 study in Gastroesophageal RefluxChong Kun Dang Pharmaceutical · NCT03558425 · 41 enrolled · Korea, Republic of
- Mar 18, 2019Phase 1 study in Heathy VolunteerHanmi Pharmaceutical · NCT03882112 · 24 enrolled · Korea, Republic of
- Sep 4, 2019Phase 3 study in Erosive Gastroesophageal Reflux DiseaseHanmi Pharmaceutical · NCT04080726 · 213 enrolled · Korea, Republic of
- Dec 17, 2019Phase 1 study in Healthy VolunteerHanmi Pharmaceutical · NCT04204629 · 25 enrolled · Korea, Republic of
- Mar 26, 2020Phase 3 study in Non-erosive Gastroesphageal Reflux DiseaseHanmi Pharmaceutical · NCT04325620 · 208 enrolled · Korea, Republic of
- Jan 7, 2021Phase 1 study in Gastroesophageal RefluxChong Kun Dang Pharmaceutical · NCT04703374 · 48 enrolled · Korea, Republic of
- Sep 6, 2021Genuine Research Center, Egypt’s first study: phase 1 study in HealthyNew to Genuine Research Center, EgyptGenuine Research Center, Egypt · NCT05038969 · 30 enrolled · Egypt
- Jan 31, 2022Phase 3 study in Gastroesophageal RefluxAstraZeneca · NCT05267613 · 53 enrolled · United States, Argentina, Australia and more
- Feb 22, 2022HALEON’s first study: phase 1 study in Gastrointestinal DiseasesNew to HALEONHALEON · NCT05265247 · 61 enrolled · Canada
- Feb 16, 2024Phase 1 study in HealthyPfizer · NCT06275841 · 12 enrolled · United States
- Feb 7, 2025Joincare Pharmaceutical Group Industry’s first study: phase 3 study in Esophagitis, PepticNew to Joincare Pharmaceutical Group IndustryJoincare Pharmaceutical Group Industry · NCT06850480 · 356 planned · China
TargetBeta
“Potassium-transporting ATPase inhibitor; Potassium-transporting ATPase inhibitor; Potassium-transporting ATPase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Rabeprazolerule | Eisai | phase 4 | 66 |
| Omeprazolerule | AstraZeneca | phase 4 | 56 |
| tegoprazanrule | HK inno.N | phase 4 | 48 |
| vonoprazanrule | Takeda | phase 4 | 48 |
| fexuprazanrule | Daewoong Pharmaceutical | phase 4 | 29 |
Studies
The newest 60 of 122 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06850480Esophagitis, Peptic · China | 3 | Recruiting | Joincare Pharmaceutical Group Industry | Apr 15, 2025 | 356 |
| NCT06275841Healthy · United States | 1 | Completed | Pfizer | May 3, 2024 | 12 |
| NCT05265247Gastrointestinal Diseases · Canada | 1 | Completed | HALEON | Jun 2, 2022 | 61 |
| NCT05267613Gastroesophageal Reflux · United States, Argentina, Australia and more | 3 | Completed | AstraZeneca | Aug 10, 2026 | 53 |
| NCT05038969Healthy · Egypt | 1 | Completed | Genuine Research Center, Egypt | Apr 1, 2021 | 30 |
| NCT04703374Gastroesophageal Reflux · Korea, Republic of | 1 | UNKNOWN | Chong Kun Dang Pharmaceutical | Sep 2021 | 48 |
| NCT04325620Non-erosive Gastroesphageal Reflux Disease · Korea, Republic of | 3 | Completed | Hanmi Pharmaceutical | Aug 3, 2020 | 208 |
| NCT04204629Healthy Volunteer · Korea, Republic of | 1 | Completed | Hanmi Pharmaceutical | Feb 20, 2020 | 25 |
| NCT04080726Erosive Gastroesophageal Reflux Disease · Korea, Republic of | 3 | Completed | Hanmi Pharmaceutical | Dec 3, 2019 | 213 |
| NCT03882112Heathy Volunteer · Korea, Republic of | 1 | Completed | Hanmi Pharmaceutical | Aug 28, 2019 | 24 |
| NCT03558425Gastroesophageal Reflux · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Sep 14, 2018 | 41 |
| NCT03553563Esophagitis, Peptic · Japan | 3 | Completed | AstraZeneca | Dec 27, 2022 | 50 |
| NCT03444402Gastroesophageal Reflux · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | May 4, 2018 | 18 |
| NCT03372850Healthy · Korea, Republic of | 1 | UNKNOWN | Hanmi Pharmaceutical | Jun 15, 2018 | 96 |
| NCT03083639Healthy Participants · United States | 1 | Completed | Takeda | May 13, 2017 | 52 |
| NCT02959255Helicobacter Pylori Infection · Greece | 4 | Completed | Elpen Pharmaceutical | Dec 30, 2017 | 364 |
| NCT02743949Gastroesophageal Reflux · Belgium, Bulgaria, Czechia and more | 2 | Completed | Takeda | Oct 5, 2018 | 256 |
| NCT02680132Healthy | 1 | Completed | Torrent Pharmaceuticals | May 2011 | 56 |
| NCT02680119Healthy | 1 | Completed | Torrent Pharmaceuticals | May 2011 | 56 |
| NCT02708355Heartburn · United States | 4 | Completed | Pfizer | Apr 2016 | 55 |
| NCT02670642Gastroesophageal Reflux · Austria, France, Germany and more | 3 | Completed | AstraZeneca | Nov 2002 | 877 |
| NCT02624544Psoriasis | 4 | Withdrawn | EMS | Jan 2016 | 0 |
| NCT02659683Healthy Subjects | 1 | Completed | Torrent Pharmaceuticals | May 2011 | 54 |
| NCT02552641Helicobacter Pylori Infection · Brazil | 4 | Withdrawn | EMS | Feb 2016 | 0 |
| NCT02153398Stomach Ulcer · Japan | 3 | Completed | AstraZeneca | Apr 2016 | 55 |
| NCT02157376Gastrointestinal Hemorrhage · China | 3 | Completed | AstraZeneca | Feb 2016 | 343 |
| NCT01964131Stomach Ulcer · Japan | 1 | Completed | AstraZeneca | Dec 2013 | 34 |
| NCT01757275Peptic Ulcer Hemorrhage · China | 3 | Completed | AstraZeneca | Dec 2014 | 239 |
| NCT01669811Esophagitis, Peptic · Japan | 3 | Completed | AstraZeneca | May 2014 | 1,398 |
| NCT01595425Bioequivalence Study · Japan | 1 | Completed | AstraZeneca | Jun 2012 | 71 |
| NCT01549574Healthy · Belgium | 1 | Completed | Pfizer | May 2012 | 16 |
| NCT01494402Bioequivalence Study · Japan | 1 | Completed | AstraZeneca | Mar 2012 | 77 |
| NCT01471925Gastroesophageal Reflux · Brazil | 3 | Withdrawn | Eurofarma Laboratorios | 0 | |
| NCT01397084Gastroesophageal Reflux | 4 | Completed | AstraZeneca | Jan 2012 | 107 |
| NCT01370538Heartburn · United States | 3 | Completed | AstraZeneca | Oct 2011 | 341 |
| NCT01370525Heartburn · United States | 3 | Completed | AstraZeneca | Oct 2011 | 340 |
| NCT01358383Arthritis, Juvenile · United States | 1 | Completed | AstraZeneca | Jun 2011 | 28 |
| NCT01249651Heartburn · China | 4 | Completed | AstraZeneca | Jun 2011 | 101 |
| NCT01210339Cardiovascular Diseases · Sweden | 1 | Completed | AstraZeneca | Aug 2011 | 58 |
| NCT01199328Peptic Ulcer · United States | 1 | Completed | AstraZeneca | Nov 2010 | 34 |
| NCT01163630Effect of Food · United States | 1 | Completed | AstraZeneca | Sep 2010 | 24 |
| NCT01159145Pharmacodynamics Study · Japan | 1 | Completed | AstraZeneca | Sep 2010 | 42 |
| NCT01119768Non-Erosive Reflux Disease · China | 4 | Completed | AstraZeneca | Jun 2011 | 305 |
| NCT01094483Platelet Inhibition · United States | 1 | Completed | AstraZeneca | May 2010 | 40 |
| NCT01069939Stomach Ulcer · Japan, Korea, Republic of, Taiwan | 3 | Completed | AstraZeneca | Nov 2011 | 427 |
| NCT01015729Peptic Ulcer · Canada | 1 | Terminated | AstraZeneca | 30 | |
| NCT00998075Peptic Ulcer · Canada | 1 | Completed | AstraZeneca | Dec 2009 | 138 |
| NCT00992381Healthy · Australia | 1 | Completed | AstraZeneca | 24 | |
| NCT00942175Stomach Ulcer · United States | 1 | Completed | Takeda | Jun 2010 | 160 |
| NCT00930215Healthy · Japan | 1 | Completed | AstraZeneca | 48 | |
| NCT00907400Healthy · Sweden | 1 | Completed | AstraZeneca | Sep 2009 | 48 |
| NCT00825630Helicobacter Pylori Infection · Israel | 4 | Completed | SD Biosensor | Nov 2009 | 123 |
| NCT00761501Healthy Volunteer · Sweden | 1 | Completed | AstraZeneca | Dec 2008 | 38 |
| NCT00734097Gastroesophageal Reflux · Argentina, Chile, Colombia and more | 4 | Completed | AstraZeneca | Oct 2008 | 314 |
| NCT00692055Arthritis · United States | 1 | Completed | Aralez Pharmaceuticals | Jul 2008 | 30 |
| NCT00688428Ulcer | 1 | Completed | AstraZeneca | Apr 2008 | 84 |
| NCT00687245Gastroesophageal Reflux | 1 | Completed | AstraZeneca | May 2008 | 40 |
| NCT00684190Gastroesophageal Reflux · Sweden | 1 | Completed | AstraZeneca | Jun 2008 | 30 |
| NCT00676442Arthritis · United States | 1 | Completed | Aralez Pharmaceuticals | Jun 2008 | 24 |
| NCT00676117Healthy · Japan | 1 | Completed | AstraZeneca | Jul 2008 | 30 |
How it is read
Names in the registry
- “Esomeprazole”, 72 entries
- “esomeprazole”, 8 entries
- “PN400”, 8 entries
- “Esomeprazole (Nexium)”, 3 entries
- “HIP1601”, 3 entries
Codes read as this program: D961H, D026.
Conditions, from the studies’ own filings
- Gastroesophageal Reflux, 40 studies
- Stomach Ulcer, 13 studies
- Heartburn, 9 studies
- Esophagitis, Peptic, 6 studies
- Gastrointestinal Diseases, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.